151 related articles for article (PubMed ID: 35757139)
1. Sudden Onset of Severe Pulmonary Hypertension in a Preterm Infant: A Case Report on the Role of Maternal Use of Serotonin Re-Uptake Inhibitors During Pregnancy and Concurrent Risk Factors.
Buffoni I; Buratti S; Mallamaci MF; Pezzato S; Lampugnani E; Buffelli F; Fulcheri E; Moscatelli A
Front Pediatr; 2022; 10():855419. PubMed ID: 35757139
[TBL] [Abstract][Full Text] [Related]
2. Factors relating caesarean section to persistent pulmonary hypertension of the newborn.
Babooa N; Shi WJ; Chen C
World J Pediatr; 2017 Dec; 13(6):517-527. PubMed ID: 29058246
[TBL] [Abstract][Full Text] [Related]
3. Hypothesis: selective phosphodiesterase-5 inhibition improves outcome in preeclampsia.
Downing JW; Ramasubramanian R; Johnson RF; Minzter BH; Paschall RL; Sundell HW; Engelhardt B; Lewis R
Med Hypotheses; 2004; 63(6):1057-64. PubMed ID: 15504576
[TBL] [Abstract][Full Text] [Related]
4. Persistent pulmonary hypertension of the newborn is associated with mode of delivery and not with maternal use of selective serotonin reuptake inhibitors.
Wilson KL; Zelig CM; Harvey JP; Cunningham BS; Dolinsky BM; Napolitano PG
Am J Perinatol; 2011 Jan; 28(1):19-24. PubMed ID: 20607643
[TBL] [Abstract][Full Text] [Related]
5. Fetal growth restriction and intra-uterine growth restriction: guidelines for clinical practice from the French College of Gynaecologists and Obstetricians.
Vayssière C; Sentilhes L; Ego A; Bernard C; Cambourieu D; Flamant C; Gascoin G; Gaudineau A; Grangé G; Houfflin-Debarge V; Langer B; Malan V; Marcorelles P; Nizard J; Perrotin F; Salomon L; Senat MV; Serry A; Tessier V; Truffert P; Tsatsaris V; Arnaud C; Carbonne B
Eur J Obstet Gynecol Reprod Biol; 2015 Oct; 193():10-8. PubMed ID: 26207980
[TBL] [Abstract][Full Text] [Related]
6. Management of preeclampsia.
Dekker GA
Pregnancy Hypertens; 2014 Jul; 4(3):246-7. PubMed ID: 26104648
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of antenatal steroids in obstetric subgroups.
Elimian A; Verma U; Canterino J; Shah J; Visintainer P; Tejani N
Obstet Gynecol; 1999 Feb; 93(2):174-9. PubMed ID: 9932550
[TBL] [Abstract][Full Text] [Related]
8. Identifying late-onset fetal growth restriction by measuring circulating placental RNA in the maternal blood at 28 weeks' gestation.
Whitehead CL; McNamara H; Walker SP; Alexiadis M; Fuller PJ; Vickers DK; Hannan NJ; Hastie R; Tuohey L; Kaitu'u-Lino TJ; Tong S
Am J Obstet Gynecol; 2016 Apr; 214(4):521.e1-521.e8. PubMed ID: 26880734
[TBL] [Abstract][Full Text] [Related]
9. Longitudinal maternal hemodynamics in pregnancies affected by fetal growth restriction.
Stott D; Papastefanou I; Paraschiv D; Clark K; Kametas NA
Ultrasound Obstet Gynecol; 2017 Jun; 49(6):761-768. PubMed ID: 27854379
[TBL] [Abstract][Full Text] [Related]
10. Nonsteroidal antiinflammatory drugs in late pregnancy and persistent pulmonary hypertension of the newborn.
Van Marter LJ; Hernandez-Diaz S; Werler MM; Louik C; Mitchell AA
Pediatrics; 2013 Jan; 131(1):79-87. PubMed ID: 23209104
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for persistent pulmonary hypertension of the newborn.
Hernández-Díaz S; Van Marter LJ; Werler MM; Louik C; Mitchell AA
Pediatrics; 2007 Aug; 120(2):e272-82. PubMed ID: 17671038
[TBL] [Abstract][Full Text] [Related]
12. Pregnancy outcome and placental findings in pregnancies complicated by fetal growth restriction with and without preeclampsia.
Kovo M; Schreiber L; Elyashiv O; Ben-Haroush A; Abraham G; Bar J
Reprod Sci; 2015 Mar; 22(3):316-21. PubMed ID: 25001023
[TBL] [Abstract][Full Text] [Related]
13. Risk of stillbirth, preterm delivery, and fetal growth restriction following exposure in a previous birth: systematic review and meta-analysis.
Malacova E; Regan A; Nassar N; Raynes-Greenow C; Leonard H; Srinivasjois R; W Shand A; Lavin T; Pereira G
BJOG; 2018 Jan; 125(2):183-192. PubMed ID: 28856792
[TBL] [Abstract][Full Text] [Related]
14. First trimester preeclampsia screening and prediction.
Chaemsaithong P; Sahota DS; Poon LC
Am J Obstet Gynecol; 2022 Feb; 226(2S):S1071-S1097.e2. PubMed ID: 32682859
[TBL] [Abstract][Full Text] [Related]
15. Impact of new definitions of preeclampsia at term on identification of adverse maternal and perinatal outcomes.
Lai J; Syngelaki A; Nicolaides KH; von Dadelszen P; Magee LA
Am J Obstet Gynecol; 2021 May; 224(5):518.e1-518.e11. PubMed ID: 33166504
[TBL] [Abstract][Full Text] [Related]
16. Pravastatin plus L-arginine prevents adverse pregnancy outcomes in women with uteroplacental vascular dysfunction.
Jurisic A; Jurisic Z; Lefkou E; Girardi G
Vascul Pharmacol; 2021 Apr; 137():106824. PubMed ID: 33249273
[TBL] [Abstract][Full Text] [Related]
17. MOS HIP: McMaster outcome study of hypertension in pregnancy.
Ray JG; Burrows RF; Burrows EA; Vermeulen MJ
Early Hum Dev; 2001 Sep; 64(2):129-43. PubMed ID: 11440825
[TBL] [Abstract][Full Text] [Related]
18. Risk factors for persistent pulmonary hypertension of the newborn.
Delaney C; Cornfield DN
Pulm Circ; 2012; 2(1):15-20. PubMed ID: 22558515
[TBL] [Abstract][Full Text] [Related]
19. Immediate versus deferred delivery of the preterm baby with suspected fetal compromise for improving outcomes.
Stock SJ; Bricker L; Norman JE; West HM
Cochrane Database Syst Rev; 2016 Jul; 7(7):CD008968. PubMed ID: 27404120
[TBL] [Abstract][Full Text] [Related]
20. Infant outcome after active management of early-onset fetal growth restriction with absent or reversed umbilical artery blood flow.
Morsing E; Brodszki J; Thuring A; Maršál K
Ultrasound Obstet Gynecol; 2021 Jun; 57(6):931-941. PubMed ID: 32862450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
